Enveric Biosciences Inc ENVB.OQ ENVB.O is expected to show no change in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Enveric Biosciences Inc is for a loss of 23 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Enveric Biosciences Inc is $54.80, above its last closing price of $1.73.
This summary was machine generated March 21 at 12:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)